Temafloxacin: Assay Workflows and Optimization
2026-08-28
Temafloxacin supports concentration-controlled testing across respiratory, intracellular, and mixed bacterial models. This practical guide combines MIC design, intracellular assay handling, formulation controls, and a process-optimization lesson from glycopeptide production research.
Tobramycin: From MIC Data to Better Assays
2026-08-28
Tobramycin is an aminoglycoside antibiotic whose historical comparator data can guide modern assay design. This evidence-focused article explains how inoculum, isolate selection, and endpoint choice shape interpretable microbiology and antibiotic resistance research.
Ceftolozane Sulfate: Applied Research Workflows
2026-08-27
Build reproducible susceptibility, time-kill, and PK/PD workflows around Ceftolozane sulfate for resistant Gram-negative research. The approach combines PBP-focused mechanistic testing with isolate-level resistance profiling and translational infection models.
Cefodizime: A Resistance-Aware Research Framework
2026-08-27
Cefodizime is a third-generation cephalosporin antibiotic whose PBP targeting and broad antibacterial profile make it valuable for resistance-aware microbiology research. This article connects hospital surveillance data with practical assay design, spectrum controls, and responsible interpretation.
Dicloxacillin Activity Inside and Outside S. aureus
2026-08-26
The reference study integrated THP-1 intracellular assays with a murine peritonitis model to compare dicloxacillin activity against extracellular and cell-associated Staphylococcus aureus. Its central translational finding was that free-drug time above the MIC best predicted efficacy in both compartments, while repeated dosing improved bacterial clearance more clearly than single-dose exposure.
Vemurafenib: Assay Design for BRAF-Mutant Melanoma
2026-08-26
Vemurafenib and PLX4032 are examined through an assay-design framework for BRAF-mutant melanoma research. This guide connects target engagement, paradoxical RAF signaling, xenograft interpretation, and ARID1A-associated resistance to practical experimental decisions.
U-73122: Applied PLC Signaling Workflows
2026-08-25
U-73122 is a phospholipase C inhibitor for separating PLC-dependent calcium signaling, chemotaxis, inflammation, and cancer-cell invasion from downstream phenotypes. This practical guide combines dose-ranging, calcium-flux and migration workflows with controls that improve interpretability and reproducibility.
CLCC1 Promotes Herpesvirus Nuclear Egress Fusion
2026-08-25
This preprint identifies the host protein CLCC1 as an essential factor in the membrane-fusion stage of herpesvirus nuclear egress, a step required to release capsids from the nuclear envelope. A whole-genome CRISPR screen with HSV-1 linked CLCC1 loss to perinuclear capsid accumulation, reduced viral production, and defective nuclear pore complex insertion in uninfected cells.
Cefazedone: From MIC to PK/PD Translation
2026-08-24
Cefazedone (Refosporen) is examined through a translational lens, connecting antibacterial testing in vitro with validated plasma quantification and PK/PD interpretation. This article explains how the evidence supports better assay design, compound handling, and interpretation of cefazedone MIC values.
Regorafenib (BAY 73-4506) Melanoma Workflows
2026-08-23
Build reproducible melanoma, angiogenesis, and metastasis experiments with Regorafenib (BAY 73-4506), from kinase-pathway validation to migration, invasion, apoptosis, and tumor xenograft models. This workflow connects the compound’s multikinase profile with the reference study’s RRM2–ERK/E2F3 mechanism to improve assay selection and troubleshooting.
PEO Chain Density and Uremic Toxin Adsorption
2026-08-22
The reference study examines how end-tethered methoxy-poly(ethylene oxide) chain density affects the adsorption of 25 uremic toxins onto model gold surfaces. Its central finding is that adsorption is governed more by toxin-specific chemical structure than by solution concentration alone, providing a more realistic framework for evaluating low-fouling biomaterials in renal disease settings.
Ceftolozane/Tazobactam: Mechanism, PK/PD, and Evidence
2026-08-21
The reference review positions ceftolozane/tazobactam as an advanced antipseudomonal β-lactam combination whose value comes from potent PBP-mediated activity, stability against selected resistance mechanisms, and exposure-driven pharmacodynamics. Its integrated discussion of microbiology, animal models, pharmacokinetics, clinical dosing, and safety provides a useful framework for interpreting Ceftolozane research against resistant Gram-negative pathogens.
Ceftolozane/Tazobactam Dosing in Pseudomonas Bacteremia
2026-08-21
This reference study used clinical susceptibility data and renal function–stratified pharmacokinetic simulations to examine ceftolozane/tazobactam target attainment in Pseudomonas aeruginosa bacteremia. Its main practical implication is that standard exposure is usually sufficient for a conventional time-above-MIC target, whereas a 2 g/1 g regimen delivered by extended infusion is more dependable when complete interval coverage is desired, particularly with high renal clearance.
METTL14–DHRS4-AS1 Axis in Ulcerative Colitis
2026-08-20
A 2024 Cell Biology and Toxicology study identifies METTL14-dependent m6A modification of the lncRNA DHRS4-AS1 as a protective mechanism in ulcerative colitis. Its cell and mouse experiments connect this RNA modification to the miR-206/A3AR pathway, NF-κB activation, epithelial apoptosis, and intestinal inflammation, offering a mechanistic framework for future target validation.
SB202190 (FHPI) for Reliable p38 Assays
2026-08-20
This scenario-based guide explains how SB202190 (FHPI), SKU A1632, can support reproducible p38 MAPK inhibition studies in viability, proliferation, inflammation, and cancer models. It connects compound handling, assay optimization, assembloid interpretation, and practical vendor selection to documented biochemical and formulation data.
460 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page